Thermo Fisher’s innovative carbon calculator to promote sustainability in the clinical trial setting

Image Credit: Clinical Trial Arena

Announcement

The Thermo Fisher Scientific’s PPD™ clinical research business holder and the global leader in delivering science has introduced its innovative clinical trial carbon calculator. The innovative clinical trial carbon calculator is engineered to support research sponsors and biopharmaceutical companies. Alongside mitigating and understanding the environmental impact of their clinical trials.

New approach to shift clinical trials for better

The clinical trials are crucial to advance medicine, but the environmental impact caused by the trials has remained a topic of attention and action in the vast healthcare market. According to the research, reading the single huge phase 3 clinical trial shows an ability to create around 3,000 metric tons of CO2 equivalent gases, similar to the 176 americans annual emissions. The carbon footprint has expanded throughout the industries, where the carbon presence of the worldwide clinical streamline can challenge the whole nation, just like the Caicos and British Virgin Islands or Turks.

The senior director, environmental sustainability, Thermo Fisher Scientific, Michael J. Cohen, said, “The industry is dedicated to enhancing human health, also we’re equally liable and hold the responsibility to safeguard the planet. Our new carbon calculator enables the sponsors to read the insightful details they need to make sustainable and data-fueled choices in trial design prior to the fossil fuels and waste being burned. Our main goal is to support practitioners in addressing major areas where we can bring initiatives for decarbonization.”

Sustainable approach in the clinical trials

The carbon calculator is an open-access tool that delivers a proven framework for calculating emissions throughout each phase of the study. Including patient travel to lab sample processing, site operations and investigational product manufacturing. The contribution of the calculative analysis of the activities-based total emissions tools helps users address the loudest impact of the ‘carbon hotspots’ and compare the study designs for the CO2e efficiency level. Alongside, execute strategies to mitigate emissions without sacrificing compliance and quality.

For instance, the hybrid or decentralised trial models, the one that accelerates virtual visits and remote monitoring, is capable of prominently alleviating emissions linked to on-site and travel activity. This approach is an effort mirroring the massive vision of the PPD clinical research business to improve sustainability throughout the clinical development spectrum. Via partnership with vendors, investigative sites and sponsors, the company focuses on unifying the environmental responsibility covering all stages of study execution and planning.